Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer...

Area of Science:

• Oncology
• Immunotherapy
• Dermatology

Background:

• Metastatic squamous cell skin cancer (mSCSSC) refractory to standard therapies presents a significant clinical challenge with limited treatment options.
• Recent studies indicate promising efficacy of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, in head and neck squamous cell carcinoma.
• Histological similarities between skin and head and neck squamous cell carcinoma suggest potential efficacy of PD-1 blockade in mSCSSC.

Observation:

• This report details a patient with refractory mSCSSC who received nivolumab.
• The patient demonstrated a positive clinical response to nivolumab over a 5-month period.
• A severe hemolytic crisis occurred after eight applications of nivolumab.

Findings:

• Nivolumab demonstrated therapeutic efficacy in a patient with refractory metastatic squamous cell skin cancer.
• The patient experienced a significant response for five months.
• Treatment with nivolumab was complicated by a serious adverse event: hemolytic crisis.

Implications:

• Nivolumab may represent a potential therapeutic option for patients with refractory metastatic squamous cell skin cancer.
• The occurrence of a hemolytic crisis highlights the need for careful monitoring of patients undergoing nivolumab treatment for skin cancers.
• Further clinical investigation is warranted to establish the safety and efficacy profile of nivolumab in this patient population.